Travere Therapeutics, Inc.
NASDAQ:TVTXBiotechnology
+$0.65 today
- Market cap
- $4.82B
- Beta
- 1.14
- P/E (TTM)
- -235.0
- EPS (TTM)
- -$0.23
Volume 0.84M
Average 2.31M
TVTX Depreciation & Amortization
Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.
Travere Therapeutics, Inc.NASDAQ: TVTX
Depreciation & Amortization · Q3 FY2026 · quarter ended Sep 2026
Depreciation & amortization remains negative
Q3 FY2026 depreciation & amortization was $0, compared with $15.79M a year earlier. Trailing-twelve-month depreciation & amortization was $47.58M. Over 3 fiscal years it compounded at +43.1% a year.
Context
- Depreciation & amortization amounted to 12.4% of revenue in FY2025, down 6.3 pp from a year earlier.
- Depreciation & amortization increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly depreciation & amortization holds near $0 or moves back toward the trailing-twelve-month quarterly average of $11.9M.
Sources:Income StatementText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the income statement
- Latest · FY2025
- 60.74M USD
- Year-over-year change
- +39.5%
- 4-year CAGR
- +47.8%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 60.74M | +39.5% |
| FY2024 | 2024-12-31 | 43.56M | +13.0% |
| FY2023 | 2023-12-31 | 38.53M | +86.0% |
| FY2022 | 2022-12-31 | 20.72M | +62.6% |
| FY2021 | 2021-12-31 | 12.75M | — |
Depreciation & Amortization vs competitors
How TVTX compares with its peers on the latest reported figures
- TVTX's LTM Sep 2026 depreciation & amortization of $47.58M is the highest of the 5 companies compared; the peer median is $4.09M.
- Its year-over-year change of -13.0% is the 3rd highest of 5, against a peer median of -19.2%.
- Depreciation & amortization amounts to 7.3% of revenue for TVTX, versus a peer median of 10.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $47.58M | -13.0% | +43.1% | 7.3% | |
| LTM Mar 2026 | $11.75M | -9.8% | -6.6% | 3.2% | |
| LTM Mar 2026 | $6.02M | +1.6% | +29.4% | 677.4% | |
| LTM Mar 2026 | $2.16M | -28.6% | -14.3% | 10.8% | |
| LTM Jun 2026 | $39K | -31.6% | — | — | |
| Peer median (excluding TVTX) | $4.09M | -19.2% | -6.6% | 10.8% | |
Competitors are the stored peer set for TVTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 131.84M | 109.46M | 145.24M | 233.18M | 490.73M |
| Cost of Revenue | 3.82M | 4.42M | 11.45M | 7.74M | 10.34M |
| Gross Profit | 128.02M | 105.04M | 133.79M | 225.43M | 480.39M |
| Gross Margin | 97.1% | 96.0% | 92.1% | 96.7% | 97.9% |
| Research & Development | 201.16M | 227.33M | 244.99M | 282.7M | 206.01M |
| Selling, General & Admin | 126.28M | 197.52M | 265.54M | 264.12M | 337.2M |
| Operating Expenses | 327.44M | 424.85M | 521.93M | 549.26M | 543.21M |
| Depreciation & Amortization | 12.75M | 20.72M | 38.53M | 43.56M | 60.74M |
| EBITDA | (184.46M) | (299.42M) | (326.25M) | (265.77M) | 22.22M |
| EBITDA Margin | -139.9% | -273.5% | -224.6% | -114.0% | 4.5% |
| Operating Income | (199.43M) | (319.81M) | (388.14M) | (323.83M) | (62.82M) |
| Operating Margin | -151.3% | -292.2% | -267.2% | -138.9% | -12.8% |
| Interest Income | 1.99M | 6.28M | 21.77M | 17.82M | 12.72M |
| Interest Expense | 19.68M | 11.01M | 11.33M | 11.18M | 10.75M |
| Other Income / Expenses | (17.46M) | (11.34M) | 12.03M | 3.32M | 13.55M |
| Income Before Tax | (216.88M) | (331.16M) | (376.11M) | (320.51M) | (49.27M) |
| Pre-Tax Margin | -164.5% | -302.5% | -259.0% | -137.5% | -10.0% |
| Income Tax Expense | 409K | 313K | 223K | 120K | 988K |
| Net Income | (180.09M) | (278.48M) | (111.4M) | (321.55M) | (25.55M) |
| Net Margin | -136.6% | -254.4% | -76.7% | -137.9% | -5.2% |
| EPS (Basic) | (3.01) | (4.37) | (1.50) | (4.08) | (0.56) |
| EPS (Diluted) | (3.01) | (4.37) | (1.50) | (4.08) | (0.56) |
| Weighted Avg Shares | 59.83M | 63.76M | 74.27M | 78.89M | 89.21M |
| Weighted Avg Shares (Diluted) | 59.83M | 63.76M | 74.27M | 78.89M | 89.21M |
Travere Therapeutics, Inc.
NASDAQ:TVTX
Intrinsic Alpha fair value
Locked
Current Price
$50.24
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.